Видео ютуба по тегу Tyrosine Kinase Inhibitor

Tyrosine Kinase Inhibitors (TKIs) - Imatinib (Gleevec) - Pharmacology - CML and ALL
Tyrosine Kinase Inhibitors (TKIs) - Imatinib (Gleevec) - Pharmacology - CML and ALL
HCC Whiteboard #2: The Mechanisms of Action of Tyrosine Kinase Inhibitors
HCC Whiteboard #2: The Mechanisms of Action of Tyrosine Kinase Inhibitors
An Overview of Bruton Tyrosine Kinase Inhibition
An Overview of Bruton Tyrosine Kinase Inhibition
Bruton Tyrosine Kinase Inhibitors
Bruton Tyrosine Kinase Inhibitors
HCC Whiteboard #3: The Management of Adverse Events of Tyrosine Kinase Inhibitors
HCC Whiteboard #3: The Management of Adverse Events of Tyrosine Kinase Inhibitors
The future of tyrosine kinase inhibitors for melanoma and open questions
The future of tyrosine kinase inhibitors for melanoma and open questions
Immuno-oncology agents plus tyrosine kinase inhibitors?
Immuno-oncology agents plus tyrosine kinase inhibitors?
For physicians: VEGF tyrosine kinase inhibitor treatment risks | Dana-Farber Cancer Institute
For physicians: VEGF tyrosine kinase inhibitor treatment risks | Dana-Farber Cancer Institute
Update on the efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukemia
Update on the efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukemia
Dr. Grigg on Frontline Tyrosine Kinase Inhibitors in RCC
Dr. Grigg on Frontline Tyrosine Kinase Inhibitors in RCC
Highlights From Bruton’s Tyrosine Kinase Inhibitors
Highlights From Bruton’s Tyrosine Kinase Inhibitors
Inhibition of ABL tyrosine kinases shows potential for metastatic cancer treatment
Inhibition of ABL tyrosine kinases shows potential for metastatic cancer treatment
Antibody Arrays to Assess resistance to Tyrosine kinase inhibitors | Protocol Preview
Antibody Arrays to Assess resistance to Tyrosine kinase inhibitors | Protocol Preview
Use of VEGF-Targeted Tyrosine Kinase Inhibitors
Use of VEGF-Targeted Tyrosine Kinase Inhibitors
MicroRNAs' role in Tyrosine Kinase Inhibitor resistance and their potential as indicators
MicroRNAs' role in Tyrosine Kinase Inhibitor resistance and their potential as indicators
Anti-PD1 or tyrosine kinase inhibitors?
Anti-PD1 or tyrosine kinase inhibitors?
Ibrutinib, Bruton’s tyrosine kinase inhibitor, for non-Hodgkin lymphoma
Ibrutinib, Bruton’s tyrosine kinase inhibitor, for non-Hodgkin lymphoma
Short topics: Tyrosine kinase inhibitors
Short topics: Tyrosine kinase inhibitors